Abstract
Russian recommendations for pulmonary arterial hypertension associated with congenital heart disease in adults, is designed based
on the published international recommendations and more than 50 years of experience in the treatment of patients with congenital
heart disease and pulmonary hypertension in A.N. Bakoulev Scientific Center for Cardiovascular Surgery.
Modern classification of pulmonary arterial hypertension in congenital heart disease, its diagnosis algorithms (including vasoreactivity),
surgical and medical treatment are presented. Separate analysis of pulmonary arterial hypertension in patients with univentricular
hemodynamics.
References
1. Galiè N., Humbert M., Vachiery J.L., Gibbs S., Lang I., Torbicki
A. et al. 2015 ESC/ERS Guidelines for the diagnosis and
treatment of pulmonary hypertension: The joint task force for
the diagnosis and treatment of pulmonary hypertension of the
European Society of Cardiology (ESC) and the European
Respiratory Society (ERS): Endorsed by: Association for
European Paediatric and Congenital Cardiology (AEPC),
International Society for Heart and Lung Transplantation
(ISHLT). Eur. Heart J. 2016; 37 (1): 67.
2. Galiè N., Simonneau G. (eds). Updates in pulmonary hypertension
proceedings of the 5th World Symposium on
Pulmonary Hypertension. J. Am. Coll. Cardiol. 2013; 62
(25, suppl. D).
3. Чазова И.Е., Мартынюк Т.В. (ред.). Легочная гипертензия.
М.; 2015.
4. Choussat A., Fontan F., Besse P. Selection criteria for Fontan's
procedure. In: Anderson R.H, Shineborne E.A. (eds). Pediatric
cardiology. Edinburgh: Churchhill Livingstone; 1977: 559–70.
5. Hosein R.B., Clarke A.J., McGuirk S.P., Griselli M., Stumper
O., De Giovanni J.V. et al. Factors influencing early and
late outcome following the Fontan procedure in the current
era. The ''Two Commandments''? Eur. J. Cardiothorac. Surg.
2007; 31 (3): 344–52.
6. Cerro M.J., Abman S., Diaz G., Freudenthal A.H., Freudenthal
F., Harikrishnan S. et al. A consensus approach to the
classification of pediatric pulmonary hypertensive vascular
disease: Report from the PVRI Pediatric Taskforce, Panama
2011. Pulm. Circ. 2011; (2): 286–98.
7. Dimopoulos K., Wort S.J., Gatzoulis M.A. Pulmonary hypertension
related to congenital heart disease: a call for action.
Eur. Heart J. 2014; 35 (11): 691–700.
8. Nadas A.S., Fyler D.F. Pediatric cardiology. Philadelphia:
WB Saunders; 1972: 684.
9. Heath D., Edwards J.E. The pathology of hypertensive pulmonary
vascular disease. Circulation. 1958; 18: 533–47.
10. Baumgartner H., Bonhoeffer P., De Groot N.M., de Haan F.,
Deanfield J.E., Galie N. et al. ESC Guidelines for the management
of grown-up congenital heart disease (new version
2010). Eur. Heart J. 2010; 31 (23): 2915–57.
11. D'Alto M., Mahadevan V.S. Pulmonary arterial hypertension
associated with congenital heart disease. Eur. Respir. Rev.
2012; 21 (126): 328–37.
12. Gorbachevsky S.V., Shmalts A.A., Zaets S.B. What can cause
pulmonary vascular disease in functionally single ventricle?
Anat. Physiol. 2016; 6 (1): 1000е137. Available at:
http: //dx.doi.org/10.4172/2161-0940.1000e137.
13. Therrien J., Rambihar S., Newman B., Siminovitch K.,
Langleben D., Webb G. et al. Eisenmenger syndrome and atrial
septal defect: nature or nurture? Can. J. Cardiol. 2006; 22:
1133–6.
14. Manes A., Palazzini M., Leci E., Bacchi Reggiani M.L., Branzi
A., Galiè N. Current era survival of patients with pulmonary
arterial hypertension associated with congenital heart disease:
a comparison between clinical subgroups. Eur. Heart J. 2014;
35 (11): 716–24.
15. D'Alto M., Romeo E., Argiento P., Correra A., Santoro G.,
Gaio G. et al. Hemodynamics of patients developing pulmonary
arterial hypertension after shunt closure. Int. J.
Cardiol. 2013; 168 (4): 3797–801.
16. D'Alto M., Romeo E., Argiento P., Santoro G., Sarubbi B.,
Gaio G. et al. Pulmonary vasoreactivity predicts long-term
outcome in patients with Eisenmenger syndrome receiving
bosentan therapy. Heart Br. Card. Soc. 2010; 96: 1475–9.
17. Post M.C., Janssens S., Van de Werf F., Budts W.
Responsiveness to inhaled nitric oxide is a predictor for midterm
survival in adult patients with congenital heart defects
and pulmonary arterial hypertension. Eur. Heart J. 2004; 25:
1651–6.
18. Бураковский В.И., Бухарин В.А., Плотникова Л.Р. Легочная
гипертензия при врожденных пороках сердца. М.: Медици-
на; 1975.
19. Горбачевский С.В., Шмальц А.А. Гипертензионная сосу-
дистая болезнь легких, ассоциированная с врожденными
пороками сердца. В кн.: Детская кардиохирургия. Руковод-
ство для врачей. М.: НЦССХ им. А.Н. Бакулева; 2016:
833–50.
20. Горбачевский С.В., Шмальц А.А., Белкина М.В. Гренаде-
ров М.А., Барышникова И.Ю., Пурсанов М.Г. и др. Алго-
ритм диагностики гипертензионной сосудистой болезни
легких, ассоциированной с врожденными пороками серд-
ца. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. 2015;
16 (3, прилож.): 12.
21. Горбачевский С.В., Шмальц А.А., Белкина М.В., Гренаде-
ров М.А., Рахмонов К.Х. Алгоритм определения показаний
к хирургическому лечению врожденных пороков сердца с
гипертензионной сосудистой болезнью легких. Бюллетень
НЦССХ им. А.Н. Бакулева РАМН. 2015; 16 (3, прилож.): 12.
22. Lopes A.A., Leary P.W. Measurement, interpretation and use
of hemodynamic parameters. Cardiol. Young. 2009; 19
(suppl. 1): 8–12.
23. Douwes J.M., van Loon R.L., Hoendermis E.S., Vonk-
Noordegraaf A., Roofthooft M.T., Talsma M.D. et al. Acute pulmonary
vasodilator response in paediatric and adult pulmonary
arterial hypertension: occurrence and prognostic
value when comparing three response criteria. Eur. Heart J.
2011; 32 (24): 3137–46.
24. Nakanishi T. Pulmonary arterial hypertension associated with
congenital heart disease. Personal perspectives. Int. Heart J.
2015; 56 (Suppl.) S1-3. DOI: 10.1536/ihj.15-064.
25. Moller J.H., Patton C., Varco R.L., Lillehei C.W. Late results
(30 to 35 years) after operative closure of isolated ventricular
septal defect from 1954 to 1960. Am. J. Cardiol. 1991; 68:
1491–7.
26. Galie` N., Manes A., Palazzini M., Negro L., Marinelli A.,
Gambetti S. et al. Management of pulmonary arterial hypertension
associated with congenital systemic-to-pulmonary
shunts and Eisenmenger's syndrome. Drugs. 2008; 68:
1049–66.
27. Kaemmerer H., Niwa K., Oechslin E., Ewert P., Webb G.D.,
Hess J. Pulmonary arterial hypertension in congenital heart
disease: Eisenmenger's syndrome – a global perspective.
Bremen: UNI-MED; 2013.
28. Broberg C.S., Ujita M., Prasad S., Li W., Rubens M., Bax B.E.
et al. Pulmonary arterial thrombosis in Eisenmenger syndrome
is associated with biventricular dysfunction and
decreased pulmonary flow velocity. J. Am. Coll. Cardiol.
2007; 50: 634–42.
29. Sandoval J., Aguirre J.S., Pulido T., Martinez-Guerra M.L.,
Santos E., Alvarado P. et al. Nocturnal oxygen therapy in
patients with the Eisenmenger syndrome. Am. J. Respir. Crit.
Care Med. 2001; 164: 1682–7.
30. Diller G.P., Lammers A.E., Haworth S.G., Dimopoulos K.,
Derrick G., Bonhoeffer P. et al. A modelling study of atrial septostomy
for pulmonary arterial hypertension, and its effect on
the state of tissue oxygenation and systemic blood flow.
Cardiol. Young. 2010; 20: 25–32.
31. Broberg C.S., Bax B.E., Okonko D.O., Rampling M.W.,
Bayne S., Harries C. et al. Blood viscosity and its relationship
to iron deficiency, symptoms, and exercise capacity in adults
with cyanotic congenital heart disease. J. Am. Coll. Cardiol.
2006; 48: 356–65.
32. Rhodes C.J., Howard L.S., Busbridge M., Ashby D., Kondili E.,
Gibbs J.S. et al. Iron deficiency and raised hepcidin in idiopathic
pulmonary arterial hypertension clinical prevalence,
outcomes, and mechanistic insights. J. Am. Coll. Cardiol.
2011; 58: 300–9.
33. Galiè N., Beghetti M., Gatzoulis M.A., Granton J., Berger R.M.,
Lauer A. et al. Bosentan therapy in patients with Eisenmenger
syndrome: a multicenter, double-blind, randomized, placebocontrolled
study. Circulation. 2006; 114: 48–4.
34. Gatzoulis M.A., Beghetti M., Galiè N., Granton J., Berger R.M.,
Lauer A. et al. Longer-term bosentan therapy improves functional
capacity in Eisenmenger syndrome: results of the
BREATHE-5 open-label extension study. Int. J. Cardiol.
2007; 127: 27–32.
35. Zuckerman W.A., Leaderer D., Rowan C.A., Mituniewicz J.D.,
Rosenzweig E.B. Ambrisentan for pulmonary arterial hypertension
due to congenital heart disease. J. Am. Coll. Cardiol.
2011; 107: 1381–5.
36. Mukhopadhyay S., Sharma M., Ramakrishnan S., Yusuf J.,
Gupta M.D., Bhamri N. et al. Phosphodiesterase-5 inhibitor in
Eisenmenger syndrome: a preliminary observational study.
Circulation. 2006; 114: 1807–10.
37. Rosenzweig E.B., Kerstein D., Barst R.J. Long-term prostacyclin
for pulmonary hypertension with associated congenital
heart defects. Circulation. 1999; 99: 1858–65.
38. Tay E.L., Papaphylactou M., Diller G.P., Alonso-Gonzalez R.,
Inuzuka R., Giannakoulas G. et al. Quality of life and functional
capacity can be improved in patients with Eisenmenger
syndrome with oral sildenafil therapy. Int. J. Cardiol. 2011;
149: 372–6.
39. Zhang Z.N., Jiang X., Zhang R., Li X.L., Wu B.X., Zhao Q.H.
et al. Oral sildenafil treatment for Eisenmenger syndrome:
a prospective, open-label, multicentre study. Heart. 2011; 97:
1876–81.
40. Chau E.M., Fan K.Y., Chow W.H. Effects of chronic sildenafil
in patients with Eisenmenger syndrome versus idiopathic pulmonary
arterial hypertension. Int. J. Cardiol. 2007; 120: 301–5.
41. Rosenkranz S., Ghofrani H.A., Beghetti M., Ivy D., Frey R.,
Fritsch A. et al. Riociguat for pulmonary arterial hypertension
associated with congenital heart disease. Heart. 2015;
101 (22): 1792–9.
42. Pulido T., Adzerikho I., Channick R.N., Delcroix M., Galiè N.,
Ghofrani H.A. et al. Macitentan and morbidity and mortality in
pulmonary arterial hypertension. N. Engl. J. Med. 2013; 369
(9): 809–18.
43. Galiè N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J.,
Badesch D. et al. Sildenafil citrate therapy for pulmonary
arterial hypertension. N. Engl. J. Med. 2005; 353 (20):
2148–57.
44. Galiè N., Rubin L., Hoeper M., Jansa P., Al-Hiti H., Meyer G.
et al. Treatment of patients with mildly symptomatic pulmonary
arterial hypertension with bosentan (EARLY study):
a double-blind, randomised controlled trial. Lancet. 2008;
371: 2093–100.
45. Hebert A., Mikkelsen U.R., Thilen U., Idorn L., Jensen A.S.,
Nagy E. et al. Bosentan improves exercise capacity in adolescents
and adults after Fontan operation: the TEMPO
(Treatment with Endothelin Receptor Antagonist in Fontan
Patients, a Randomized, Placebo-Controlled, Double-Blind
Study Measuring Peak Oxygen Consumption) study.
Circulation. 2014; 130 (23): 2021–30.
46. Goldberg D.J., French B., McBride M.G., Marino B.S., Mirarchi
N., Hanna B.D. et al. Impact of oral sildenafil on exercise
performance in children and young adults after the Fontan
operation: a randomized, double-blind, placebo-controlled,
crossover trial. Circulation. 2011; 123 (11): 1185–93.
47. Shang X.K., Lu R., Zhang X., Zhang C.D., Xiao S.N., Liu M.J.
et al. Efficacy of bosentan in patients after Fontan procedures:
a double-blind, randomized controlled trial. J. Huazhong.
Univ. Sci. Technol. Med. Sci. 2016; 36 (4): 534–40.
48. Mori H., Park I.S., Yamagishi H., Nakamura M., Ishikawa S.,
Takigiku K. et al. Sildenafil reduces pulmonary vascular resistance
in single ventricular physiology. Int. J. Cardiol. 2016;
221: 122–7.
49. Hirono K., Yoshimura N., Taguchi M., Watanabe K., Nakamura
T., Ichida F. et al. Bosentan induces clinical and hemodynamic
improvement in candidates for right-sided heart bypass
surgery. J. Thorac. Cardiovasc. Surg. 2010; 140: 346–51.
50. Inuzuka R., Tatebe S., Wakiguchi S., Nakajima H., Ohtsu H.,
Dimopoulos K. et al. B-type natriuretic peptide at the early
stage of univentricular circulation reflects inadequate adaptation
to volume overload. Int. J. Cardiol. 2012; 159 (2): 88–93.
51. Iversen K., Jensen A.S., Jensen T.V., Vejlstrup N.G., So/ ndergaard
L. et al. Combination therapy with bosentan and sildenafil
in Eisenmenger syndrome: a randomized, placebocontrolled,
double-blinded trial. Eur. Heart J. 2010; 31:
1124–31.
52. D'Alto M., Romeo E., Argiento P., Sarubbi B., Santoro G.,
Grimaldi N. et al. Bosentan-sildenafil association in patients
with congenital heart disease-related pulmonary arterial
hypertension and Eisenmenger physiology. Int. J. Cardiol.
2012; 155: 378–82.
53. Montani D., Savale L., Natali D., Jaїs X., Herve P., Garcia G.
et al. Long-term response to calcium-channel blockers in nonidiopathic
pulmonary arterial hypertension. Eur. Heart J.
2010; 31: 1898–907.